Home MarketSyngene International Ltd.

Syngene International Ltd. Stock Info: As on 2017-10-19 19:45:14

Nse

505.10

3.60(0.72%)
Change%
52 Week Range
430.10
11.00
663.20
9.00
Open504.15
Day's Range401.20 - 601.80
Value Traded (in ₹ Cr.) 1.04

Bse

503.10

3.85(0.77%)
Change %
52 Week Range
430.00
11.00
663.30
9.00
Open506.25
Day's Range399.40 - 599.10
Value Traded (in ₹ Cr.) 0.20

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 149,005,789.00 74.50%
Mutual Funds/UTI 2,874,400.00 1.44%
FII 31,817,463.00 15.91%
Employee 0.00 0.00%
Public 8,779,168.00 4.39%
Government 0.00 0.00%
Others 2,945,639.00 1.47%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 6.91
Basic EPS (Rs.) 11.40
Cash EPS 15.99
BVPerShare Excl 52.85
Operating Revenue 55.57
PBDITPerShare 18.27
Dividend 1.00
NPPerShare 11.10
Current Ratio 2.52
Quick Ratio 2.45
PriceToBV 7.27
Earnings 0.02
PBDIT Margin 32.87
PBT Margin 23.32
NP Margin 19.98
Return On Assets 9.25
Retention Ratios 90.95
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1,113.10
Total Expenses 854.90
EBITDA 363.90
PBT 258.20
PAT 221.20
Net Income 221.20
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 614.90
Total Expenses 466.10
EBITDA 97.50
PBT 146.60
PAT 125.30
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 199.20
Net worth 1,052.80
Investments 276.40
Total Liability 2,389.50
Total debt 891.00
Net block 817.00
Total Assets 2,389.50
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 199.20
Net worth 1,052.80
Investments 276.40
Total Liability 2,389.50
Total debt 891.00
Net block 817.00
Total Assets 2,389.50
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

401.4 406.9 -1.35
397410.8

Banaras Beads Ltd.

59.15 60.75 -2.63
58.0563.4

Binani Industries Ltd.

79.9 78.2 2.17
7682.4

Career Point Ltd.

145.45 147.25 -1.22
140.5154.45

Dredging Corporation Of India Ltd.

534.7 541.6 -1.27
532574.45

Future Consumer Ltd.

60.6 61.25 -1.06
60.1566.8

Gateway Distriparks Ltd.

239.1 239.75 -0.27
236.7248.2
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

398.85 407 -2
397.35411

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

31.2 32.8 -4.88
31.231.2

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

60.95 59.05 3.22
58.0563.45

Binani Industries Ltd.

79.9 78.75 1.46
75.9582.5

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 312.40
Cash from investing activities -748.80
Cash from financing activities 709.40
Net change in cash 271.60

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Reliance Regular Savings Fund - Equity 1.73%
Motilal Oswal Most Focused Long Term Fund 3.48%
Motilal Oswal MOSt Focused Dynamic Equity Fund 1.41%
Canara Robeco Emerging Equities 0.69%
Axis Small Cap Fund 2.87%
Invesco India Mid N Small Cap Fund 1.62%

IDBI Bank employees to go on two-day strike from Oct 24

A section of IDBI Bank employees has given two-day strike call beginning October 24. United Forum of IDBI Bank officers and Employees have given a 2-day nationwide strike call in support of their demands, IDBI Bank said in a regulatory filing to stock exchanges. Demands include wage revision for employees and officers due for the period from November 2012 to October 2017 on the lines of the settlement in all other banks.

18-10-2017 16:12

NIIT Tech Q2 profit up 14% at Rs 67.2 cr

NIIT Technologies today posted 14.4 per cent increase in consolidated profit after tax at Rs 67.2 crore for the second quarter ended September 30. The company had registered PAT of Rs 58.9 crore in the same period a year ago. The total revenue of the company increased by about 7 per cent to Rs 745.4 crore in the reported quarter from Rs 696.7 crore in the corresponding quarter of previous fiscal. Robust sequential growth during the quarter came on the back of strong growth in the US, APAC (Asia Pacific) and India, NIIT Technologies CEO and Joint MD Arvind Thakur said in a statement. NIIT Technologies recorded 5.5 per cent growth in revenues from the US sequentially during the quarter and now contributes to 50 per cent of the revenue mix, the statement said. APAC and India represent 11 per cent and 10 per cent of the mix respectively. EMEA business declined 4.8 per cent sequentially on account of the ramp down in a key travel client resulting in the share of the region being 29 per cent of the total mix, the statement said. The company said it continued to experience traction in the banking, finance service and insurance (BFSI) segment with 5.6 per cent increase in revenues on sequential quarter basis. The BFSI sector now contributes to 42 per cent to its total revenue. Revenues from travel and transportation represent 27 per cent of NIIT Technologies' overall revenues.

18-10-2017 15:37

Ultratech Q2 down 31% to Rs 424 cr

UltraTech Cement Ltd reported 30.94 per cent decline in consolidated net profit to Rs 423.76 crore for the September quarter, 2017-18. It had clocked net profit of Rs 613.64 crore in the July- September quarter of the last financial year, UltraTech said in a BSE filing. The company's consolidated sales were up 6.35 per cent to Rs 7,091.34 crore during the quarter under review as against Rs 6,667.49 crore in the year-ago period. This quarter continued to witness increasing cost trends, attributable to increase in fuel price, UltraTech said in a statement. UltraTech's total expenses was up 11.73 per cent to Rs 6,451.45 crore as against Rs 5,773.74 crore. Profit before interest, depreciation and tax at Rs 1,550 crore was higher by 13 per cent vis a vis Rs 1,378 crore in the corresponding period of the previous year, it said. The company informed that the acquisition of the cement plants of Jaiprakash Associates Ltd and Jaypee Cement Corp Ltd has helped it augment capacity to 93 million metric tonne per annum. This acquisition will enhance the company's foot print into high growth market as Central India, Eastern UP and coastal Andhra Pradesh, where the company has been focusing to increase its presence, it said.

18-10-2017 15:14

Godfrey Phillips exits tea biz: sells 8 brands to Goodricke

Tea producer Goodricke Group today said it has acquired eight tea brands of Godfrey Phillips India (GPI) for Rs 20 crore as part of its expansion of packaged tea business. The deal will mark GPI's exit from the packaged tea business. Goodricke Group, under the deal, will have rights on trademarks, titles and brands associated with the tea business, the company said in a statement. The brands acquired are Tea City, SC Gold, Symphony, Samovar, SC Premium, Super Cup, Rangoli and Utsav. This acquisition will bring synergy to our branded tea business and help us integrate all channels and develop this department further, Goodricke Group CEO and MD AN Singh said. The producer of Darjeeling tea, Goodricke Group is a constituent of Camellia Plc. UK a global conglomerate which is into agriculture, engineering, financial services and food distribution. The sale is in line with Godfrey Phillips' decision to exit the packaged tea business which contributed less than 3 per cent of the gross turnover of the company, Godfrey Phillips said.

18-10-2017 14:19

NIIT strengthens GRB operations to drive digital change

NIIT Limited, a global leader in skills and talent development has said that it is strengthening its Global Retail Business (GRB) operations to drive its digital transformation initiatives across the country. To this end, it has announced the appointment of Ganesh Krishnamurthy as Executive Vice President & Head — Product Development & Deployment, GRB and Anjali Vaishal, as the Regional Head for Karnataka, Kerala, Goa and Pune, GRB. Ganesh will be responsible for designing educational products aligned to the industry needs while Anjali will be key to driving the digital transformation initiatives in Karnataka, Kerala, Goa and Pune. Earlier in September, Anurag Gupta had joined NIIT as the Head of its GRB India Operations to drive the goals of the Retail Business in the country. Meanwhile, shares of the company were trading at Rs 106.30 apiece, down 0.23 per cent from the previous close at 14:19 hours on BSE.

18-10-2017 14:07

Syngene Internationa - Statement Of Investor Complaints For The Quarter Ended September 30, 2017

Investor Grievance Report under Regulation 13 for the quarter ended September 30, 2017

13-Oct-2017 08:41 PM

Syngene Internationa - Compliance Certificate For The Half Year Ended September 30, 2017

Half Yearly Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015

13-Oct-2017 08:23 PM

Syngene Internationa - Compliance Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015

Half Yearly Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015

13-Oct-2017 08:21 PM

Syngene Internationa - Board Meeting Rescheduled

This is with reference to our earlier intimation dated October 5, 2017, regarding notice of Board Meeting under regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company will now be held on Wednesday, October 25, 2017, inter alia, to approve and take on record the un-audited financial results for the quarter and half year ended September 30, 2017.

The Company will organize a conference call for analysts and investors on Thursday, October 26, 2017. The details of the same will be available on the Company's website closer to the scheduled event.

13-Oct-2017 08:08 PM

Syngene Internationa - Shareholding for the Period Ended September 30, 2017

Syngene International Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017.

11-Oct-2017 01:00 PM

Syngene Internationa - Statement Of Investor Complaints For The Quarter Ended September 30, 2017

Investor Grievance Report under Regulation 13 for the quarter ended September 30, 2017

13-Oct-2017 08:41 PM

Syngene Internationa - Compliance Certificate For The Half Year Ended September 30, 2017

Half Yearly Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015

13-Oct-2017 08:23 PM

Syngene Internationa - Compliance Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015

Half Yearly Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015

13-Oct-2017 08:21 PM

Corporate Details

About Management

The Company was incorporated as Syngene International Private Limited on November 18, 1993 at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. Pursuant to a special resolution of the shareholders dated March 26, 2007, the Company was converted into a public limited company and the name of the Company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19, 2007. the Company was promoted by Kiran Mazumdar Shaw, a promoter of Biocon. On March 30, 2002, 99.9 percent of the Equity Shares of the Company were transferred to Biocon and as a result, the Company became the subsidiary of Biocon. Biocon has since been the Promoter of the Company.The details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India. Major events and milestones of the Company : 1994 -Initiated operations as a CRO with services in chemistry and biology 1998 -Granted 100% Export Oriented Unit (EOU) status by the Government of India 1999 -First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft. 2000 -CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies 2001 -Forayed into chemical development with a dedicated manufacturing facility 2003 -Moved to Biocon Park, a 90 acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft. 2007 -Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D centre -Expansion of research facilities at Biocon SEZ to 148,000 sq. ft. -Crossed an annual turnover of over `1,000 million in Financial Year 2007 2009 -Dupont Crop Protection and the Company extended a partnership for R&D services -Expansion of manufacturing services with a new plant which is cGMP compliant -Initiated operations in safety assessment and large molecules development services 2010 -Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA -Initiated operations in formulation development 2011 -Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer 2012 -Abbott and the Company collaborated to establish Abbott's nutrition research and development centre in India and the second R&D centre -Certification of the clinical facilities by ANVISA -Acquired 100% stake in Clinigene International Limited from Biocon 2013 -Crossed an annual turnover of over `5,000 million in Financial Year 2013 -Baxter International Inc. collaborated with the Company to establish the `Baxter Global Research Center', the third dedicated R&D centre -Acceptance of the control testing laboratory by the Department of Health & Human Services, FDA 2014 -Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D centre till 2020 -Acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA -Established a 75,000 sq.ft centre to provide stability and analytical services 2015 -CIL was amalgamated with the Company Awards, Recognitions and Accreditations : 2009 - Bangalore Bio, Bio Excellence Award - Biotech Services Sector - Best BioServices company of the year by Biospectrum 2012 - ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - AAALAC accreditation for conforming to the "Guide for the Care and Use of Laboratory Animals and the Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines" 2013 - Bioservices - ABLE Tenth Anniversary Award - Outstanding contribution to Bioservices - Diamond sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology 2014 - ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - Silver EDGE Award - EHS best practices award by CII - SAP Ace Award for special recognition for complex SAP implementation - Level I Laboratory certification issued by the NGSP to Clinigene International Limited 2015 - Accreditation by the College of American Pathologists in relation to their laboratory accreditation program - Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector - ISO 15189:2007 in the field of medical testing

Registered Office

113-C - 2, Bommasandra Industrial Area, Attibele Hobli, Anekal Taluk,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.